{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060352","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.405371+00:00","generated_at":"2026-06-08T16:47:49.844433+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pyxis Oncology reports Q3 2023 net loss $23.0M; cuts headcount 40% to extend cash runway into early 2026","bullets":["Net loss of $23.0M ($0.56 per share) for Q3 2023, vs $27.7M ($0.85 per share) in Q3 2022.","Cash, restricted cash, and short-term investments total $134.4M as of Sept 30, 2023.","Announces 40% headcount reduction and pausing early-stage research to extend cash runway into early 2026.","PYX-201 Phase 1 fifth dose cohort at 3.6 mg/kg; preliminary data expected 1H 2024. PYX-106 refocused on NSCLC; data expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060352","json":"https://secwatch.observer/filing/0000950170-23-060352.json","markdown":"https://secwatch.observer/filing/0000950170-23-060352.md","text":"https://secwatch.observer/filing/0000950170-23-060352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023060352/0000950170-23-060352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023060352/pyxs-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:47:49.844433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65ab238a065d461636a4351703928cf346dde15a","claim":"Pyxis Oncology, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Pyxis Oncology, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023060352/0000950170-23-060352-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}